Conditions: Breast Neoplasm Brain Neoplasm Second Neoplasm
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether temozolomide can be used as a prophylaxis against brain recurrence in participants with metastatic breast cancer.

Detailed description:
Breast cancer is the second most common cause of brain metastases. Overall survival after the development of brain metastases tends to be poor (6-8 months). Over-expression of Human Epidermal Growth Factor Receptor 2 (HER-2/neu), negative estrogen receptor, and young age at diagnosis seem to be indicators of high risk for brain metastases. Temozolomide may be a good candidate for prophylactic chemotherapy because of its ability to cross the blood-brain-barrier, achieving high concentrations in the central nervous system (CNS).

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: temozolomide
Intervention descriptions: intervention 1: Capsules to equal 75 mg/m\^2, orally, daily for 6 weeks, in 3 eight-week cycles

Protocol document: